Patents by Inventor Toby Jonathan Blench

Toby Jonathan Blench has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250171400
    Abstract: The invention provides aza-heterocyclyl carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxC activity.
    Type: Application
    Filed: January 24, 2025
    Publication date: May 29, 2025
    Inventors: Michael Dominic Ryan, Thomas David Pallin, Toby Jonathan Blench, Toby Matthew Grover Mullins, David Edward Clark, Emanuela Gancia, Nadia Mamoona Ahmad
  • Patent number: 12286411
    Abstract: The invention relates to an indane compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful for treating antibacterial infection either as stand-alone antibiotics, or in combination with further antibiotics.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: April 29, 2025
    Assignee: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Patent number: 12247013
    Abstract: The invention relates to an indane compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful for treating antibacterial infection either as stand-alone antibiotics, or in combination with further antibiotics.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 11, 2025
    Assignee: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Patent number: 12227475
    Abstract: The invention provides aza-heterocyclyl carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxC activity.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: February 18, 2025
    Inventors: Michael Dominic Ryan, Thomas David Pallin, Toby Jonathan Blench, Toby Matthew Grover Mullins, David Edward Clark, Emanuela Gancia, Nadia Mamoona Ahmad
  • Publication number: 20240374589
    Abstract: The disclosure herein provides compounds and pharmaceutical compositions of Formula (I), (II), (III), (IV), (V), or (VI) for killing cancer cell or inhibiting cancer cell proliferation. Further, the compounds and pharmaceutical compositions of Formula (I), (II), (III), (IV), (V), or (VI) are useful in methods of for the inhibition of cancer cell proliferation.
    Type: Application
    Filed: July 11, 2024
    Publication date: November 14, 2024
    Inventors: Nadia Mamoona AHMAD, Christopher Charles RENNIE, William Rameshchandra Krishna ESMIEU, Mark CHAMBERS, Toby Jonathan BLENCH, Susan Mary CRAMP, Toby Matthew Grover MULLINS, Terry Aaron PANCHAL, Joseph Leo MCKENNA
  • Publication number: 20240016941
    Abstract: The invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) one or more CFTR modulator; wherein R1, R2, R3, R4, n, Lk, (A), G and m are as defined herein. Also provided are therapeutic uses of such combinations and compositions in the treatment of conditions such as cystic fibrosis.
    Type: Application
    Filed: March 23, 2021
    Publication date: January 18, 2024
    Applicant: Antabio SAS
    Inventors: Martin Everett, Simon Leiris, David Thomas Davies, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Publication number: 20230139502
    Abstract: The invention provides aza-heterocyclyl carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxC activity.
    Type: Application
    Filed: April 27, 2022
    Publication date: May 4, 2023
    Inventors: Michael Dominic Ryan, Thomas David Pallin, Toby Jonathan Blench, Toby Matthew Grover Mullins, David Edward Clark, Emanuela Gancia, Nadia Mamoona Ahmad
  • Publication number: 20220112169
    Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.
    Type: Application
    Filed: July 25, 2019
    Publication date: April 14, 2022
    Applicant: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Publication number: 20210347748
    Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 11, 2021
    Applicant: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Patent number: 11000511
    Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: May 11, 2021
    Assignee: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Jonathan Mark Sutton, Michael Steven Bodnarchuk, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, David Edward Clark, Richard Leonard Elliott, Lilha Beyria
  • Publication number: 20200155509
    Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.
    Type: Application
    Filed: March 21, 2018
    Publication date: May 21, 2020
    Applicant: Antabio SAS
    Inventors: Simon LEIRIS, David Thomas DAVIES, Martin EVERETT, Nicolas SPRYNSKI, Jonathan Mark SUTTON, Michael Steven BODNARCHUK, Thomas David PALLIN, Andrew Peter CRIDLAND, Toby Jonathan BLENCH, David Edward CLARK, Richard Leonard ELLIOTT, Lilha BEYRIA
  • Patent number: 9023855
    Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: May 5, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
  • Publication number: 20140179714
    Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.
    Type: Application
    Filed: February 11, 2014
    Publication date: June 26, 2014
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
  • Publication number: 20140171408
    Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.
    Type: Application
    Filed: February 20, 2014
    Publication date: June 19, 2014
    Applicant: Genentech, Inc.
    Inventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum MacLeod, Steven R. Magnuson, Vickie Hsiao-Wei Tsui, Karen Williams, Birong Zhang
  • Patent number: 8697708
    Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 15, 2014
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven R. Magnuson, Vickie H. Tsui, Karen Williams, Birong Zhang
  • Patent number: 8691826
    Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: April 8, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
  • Patent number: 8546376
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: October 1, 2013
    Assignee: Almac Discovery Limited
    Inventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
  • Publication number: 20130065913
    Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.
    Type: Application
    Filed: September 13, 2012
    Publication date: March 14, 2013
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
  • Publication number: 20120238541
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Application
    Filed: September 17, 2010
    Publication date: September 20, 2012
    Applicant: Almac Discovery Limited
    Inventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
  • Publication number: 20120202788
    Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.
    Type: Application
    Filed: September 14, 2011
    Publication date: August 9, 2012
    Inventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven R. Magnuson, Vickie H. Tsui, Karen Williams, Birong Zhang